<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00905515</url>
  </required_header>
  <id_info>
    <org_study_id>MR-06-001</org_study_id>
    <nct_id>NCT00905515</nct_id>
  </id_info>
  <brief_title>Optima: Optimizing Prograf Therapy in Maintenance Allografts II</brief_title>
  <acronym>OPTIMAII</acronym>
  <official_title>Optima: Optimizing Prograf Therapy in Maintenance Allografts II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>East Carolina University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>East Carolina University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to optimize calcineurin immunosuppressive regimens and evaluate
      immunological and non-immunological markers that may explain mechanistic differences in these
      agents and their effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the major challenges in transplantation over the past two decades has been managing
      long-term renal function. Serum creatinine is the most commonly used serum marker of renal
      function. However serum creatinine is insensitive for detecting small decreases in glomerular
      filtration rate (GFR). Another marker for renal function is cystatin C. Dharnidharka et al
      concluded that cystatin C is superior to serum creatinine as a marker of kidney function
      since cystatin C was a more sensitive marker than serum creatinine for detecting decreases in
      GFR. Pirsch et al reported that tacrolimus-treated patients had a lower incidence of severe
      acute rejection and better lipid profiles than cyclosporine-treated patients.

      Cardiovascular disease is the primary cause of premature death in renal and other transplant
      recipients. Current immunosuppressive protocols often elevate cardiovascular disease risk
      factors such as hypertension, hyperlipidemia, obesity and diabetes.

      This study is designed to optimize calcineurin immunosuppressive regimens to ensure the best
      possible long-term outcomes after renal transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal Function in Patients Converted From Cyclosporine to Prograf</measure>
    <time_frame>6 months, 1 year, 2 years and 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Optimal Dose/Blood Level of Prograf in Long-term Maintenance Kidney Transplant Patients</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Risk Factors for Cardiovascular Morbidity and Chronic Graft Dysfunction as Evidenced by Blood Levels of Homocysteine and Transforming Growth Factor Beta (TGF-B)</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Maintain on Cyclosporine (CsA) at target trough level of 50-250 ng/mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Convert to Prograf (TAC) at target trough levels of 3.0-5.9 ng/mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Convert to TAC at target trough levels of 6.0-8.9 ng/mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Maintain on cyclosporine at target trough level of 50-250 ng/mL.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Cyclosporine/Neoral速/Sandimmune速/Gengraf速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf (Tacrolimus)</intervention_name>
    <description>Convert to Prograf at target trough levels of 3.0-5.9 ng/mL (Arm 2) or target trough levels of 6.0-8.9 ng/mL (Arm 3).</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Tacrolimus/Prograf速/FK506</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is the recipient of a cadervic or living donor renal transplant.

          -  Patient was 18 years of age at time of transplant.

          -  Patient is at least 6 months post-transplant.

          -  Patient has been on a cyclosporine-based immunosuppressive regimen since the
             transplant.

          -  Patient has a functioning allograft and a Cockcroft/Gault estimate of creatinine
             clearance &gt;or= 35 mL/min within four weeks prior to randomization.

          -  Patient or legal guardian has signed and dated an Institutional Review Board (IRB)
             approved informed consent document and is willing and able to follow study procedures.

          -  Females are not pregnant and agree to practice effective birth control while receiving
             immunosuppressant medication.

        Exclusion Criteria:

          -  Patient is the recipient of a solid organ transplant other than the kidney.

          -  Patient experienced biopsy-confirmed, acute rejection, (Banff 97 criteria)within 3
             months before randomization that required treatment, which is defined as
             antilymphocyte therapy, corticosteroids, or an increase in the number or dose of
             immunosuppressant medication.

          -  Patient has recurrence of primary renal disease, or de novo renal disease.

          -  Patient has a urine protein of &gt; 1.5g/24 hours or two successive urinalyses sent to
             and reported by the laboratory indicating albuminuria greater than 2+ within 6 months
             prior to enrollment.

          -  Patient has an estimated creatinine clearance &lt; 35 mL/min calculated using
             Cockcroft/Gault formula within four weeks prior to randomization.

          -  Patient has changed adjunctive immunosuppressant therapy within one month if
             randomization.

          -  Patient is pregnant or lactating.

          -  Patient is a known carrier of any of the HIV viruses.

          -  Patient has a known or suspected malignancy (except for treated squamous or basal cell
             skin cancers) &lt; 5 years before randomization or a history of post-transplant
             lymphoproliferative disease (PTLD).

          -  Patient has a known hypersensitivity to tacrolimus, or any of the excipients of the
             drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Bolin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>East Carolina University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brody School of Medicine at East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002 Aug;40(2):221-6.</citation>
    <PMID>12148093</PMID>
  </reference>
  <reference>
    <citation>Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation. 1997 Apr 15;63(7):977-83.</citation>
    <PMID>9112351</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2009</study_first_submitted>
  <study_first_submitted_qc>May 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2009</study_first_posted>
  <results_first_submitted>October 22, 2012</results_first_submitted>
  <results_first_submitted_qc>January 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2013</results_first_posted>
  <last_update_submitted>January 4, 2013</last_update_submitted>
  <last_update_submitted_qc>January 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>East Carolina University</investigator_affiliation>
    <investigator_full_name>Paul Bolin</investigator_full_name>
    <investigator_title>Chair of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Kidney Transplantation</keyword>
  <keyword>Immunosuppressive Agents</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Remaining on CsA</title>
          <description>Stable transplant recipients randomly assigned to continue on Cyclosporine (CsA( with a target trough level of 50-250 ng/mL.</description>
        </group>
        <group group_id="P2">
          <title>Reduced TAC</title>
          <description>Stable transplant recipients randomly assigned to convert to &quot;reduced&quot; Tacrolimus (TAC) with target trough levels 3.0-5.9 ng/mL.</description>
        </group>
        <group group_id="P3">
          <title>Standard TAC</title>
          <description>Stable transplant recipients randomly assigned to convert to &quot;standard&quot; TAC with target trough levels of 6.0-8.9 ng/mL.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Remaining on CsA</title>
          <description>Patients remained on CSA and were not converted to TAC.</description>
        </group>
        <group group_id="B2">
          <title>Reduced TAC</title>
          <description>Patients converted from CsA to TAC with trough concentrations 3.0-5.9 ng/mL</description>
        </group>
        <group group_id="B3">
          <title>Standard TAC</title>
          <description>Patients were converted from CsA to TAC with trough concentrations of 6.0-8.9 ng/mL</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.65" spread="12.036"/>
                    <measurement group_id="B2" value="58.57" spread="12.023"/>
                    <measurement group_id="B3" value="59.14" spread="10.011"/>
                    <measurement group_id="B4" value="58.48" spread="11.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Renal Function in Patients Converted From Cyclosporine to Prograf</title>
        <time_frame>6 months, 1 year, 2 years and 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Remaining on CsA</title>
            <description>Stable transplant recipients randomly assigned to continue on CSA with a target trough level of 50-250 ng/mL.</description>
          </group>
          <group group_id="O2">
            <title>Reduced TAC</title>
            <description>Stable transplant recipients randomly assigned to convert to &quot;reduced&quot; TAC with target trough levels 3.0-5.9 ng/mL.</description>
          </group>
          <group group_id="O3">
            <title>Standard TAC</title>
            <description>Stable transplant recipients randomly assigned to convert to &quot;standard&quot; TAC with target trough levels of 6.0-8.9 ng/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function in Patients Converted From Cyclosporine to Prograf</title>
          <units>Change in serum creatinine (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="-0.04" upper_limit="0.14"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0.10" lower_limit="-0.07" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Optimal Dose/Blood Level of Prograf in Long-term Maintenance Kidney Transplant Patients</title>
        <time_frame>6 months, 1 year, 2 years, 3 years</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Risk Factors for Cardiovascular Morbidity and Chronic Graft Dysfunction as Evidenced by Blood Levels of Homocysteine and Transforming Growth Factor Beta (TGF-B)</title>
        <time_frame>6 months, 1 year, 2 years, 3 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Remaining on CsA</title>
          <description>Patients remained on CSA and were not converted to TAC.</description>
        </group>
        <group group_id="E2">
          <title>Reduced TAC</title>
          <description>Patients converted from CsA to TAC with trough concentrations 3.0-5.9 ng/mL</description>
        </group>
        <group group_id="E3">
          <title>Standard TAC</title>
          <description>Patients were converted from CsA to TAC with trough concentrations of 6.0-8.9 ng/mL</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>New onset diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Absolute Neutrophil</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Gingival Hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Blood Glucose</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" events="23" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E3" events="17" subjects_affected="8" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hirsutism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>East Carolina University</organization>
      <phone>252-744-3773</phone>
      <email>parkerk@ecu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

